Ionis Pharmaceuticals Inc
IONS
Market Cap$6.28B
Close$
$-19.97
146.3% downside
Current Fair Value
146.3% downsideOvervalued by 146.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $6.28 Billion |
|---|---|
| Enterprise Value | $5.22 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-2.56 |
| Beta | 0.52 |
| Outstanding Shares | 145,750,000 |
| Avg 30 Day Volume | 852,353 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -17.15 |
|---|---|
| PEG | 20.83 |
| Price to Sales | 8.62 |
| Price to Book Ratio | 21.55 |
| Enterprise Value to Revenue | 6.63 |
| Enterprise Value to EBIT | -14.77 |
| Enterprise Value to Net Income | -15 |
| Total Debt to Enterprise | 0.24 |
| Debt to Equity | 3.29 |
Revenue Sources
No data
ESG Score
No data
About Ionis Pharmaceuticals Inc
817 employees
CEO: Brett Monia Ionis Pharmaceuticals is a biotechnology company based in Carlsbad, California that specializes in discovering and developing RNA-targeted therapeutics. The company has 3 commercially approved medicines: Spinraza , Tegsedi , and WAYLIVRA...